Company Analysis

Harrow, Inc. (HROW)

Nasdaq: HROW · Pharmaceutical Preparations · Nashville, TN · filing with the SEC since 2006
Grade5.8
◀ Past 5.8● Present 6.3▶ Future 5.4

Who runs Harrow, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Baum Mark L
CHIEF EXECUTIVE OFFICER. First filing Apr 2012, latest May 15, 2026, 6 filings in all.
Officers reporting now
6
of 9 people with a filing in the last fifteen months
Directors reporting now
3
19 people on the record since 2012
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Shojaei AmirCHIEF SCIENTIFIC OFFICERJan 2025Aug 17, 20261 · $500,000
Baum Mark LCHIEF EXECUTIVE OFFICERApr 2012May 15, 2026none
Boll Andrew R.PRESIDENT AND CFOMar 2012May 15, 2026none
Sullivan Patrick WilliamCHIEF COMMERCIAL OFFICERFeb 2026Feb 2, 2026none
Mullery Francis William JrCEO, ImprimisRxOct 2025Oct 10, 2025none
Pollard Randall E.CHIEF ACCOUNTING OFFICERSep 2025Sep 9, 2025none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Graves Adrienne LdirectorJan 2024Jun 22, 2026none
Silvernail Lauren PdirectorJan 2024Jun 22, 2026none
Sternberg Perry J.directorApr 2022Jun 22, 2026none
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Opaleye Management Inc.10% ownerMay 2015Mar 5, 20266 · $9.2M
Earlier names on the record12, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton HROW · research, not advice